Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Sumitomo Dainippon Pharma Co ( (JP:4506) ) is now available.
Sumitomo Pharma Co., Ltd. and Tokyo-based RACTHERA Inc. have applied for manufacturing and marketing authorization in Japan for AMCHEPRY, an allogeneic iPS cell-derived dopaminergic neural progenitor cell therapy for improving motor function during off-time in patients with advanced Parkinson’s disease. Japan’s Ministry of Health, Labour and Welfare has placed AMCHEPRY on the agenda of its Pharmaceutical Affairs and Food Sanitation Council’s Committee on Regenerative Medicine Products and Biotechnologies meeting on February 19, 2026, where a decision on approval is expected, though the company does not anticipate any impact on earnings for the fiscal year ending March 2026.
The scheduled regulatory review underscores Sumitomo Pharma’s push into cutting-edge regenerative medicine for neurodegenerative disorders, highlighting its bid to secure an early leadership position in cell-based therapies for Parkinson’s disease. While near-term financial effects are expected to be limited, a positive decision could strengthen the company’s longer-term growth prospects and competitive standing in Japan’s high-value, innovation-driven pharmaceuticals market.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen2481.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd. is a Japan-based pharmaceutical company headquartered in Osaka that develops and markets prescription drugs and regenerative medical products. The company focuses on innovative treatments, including advanced cell-based therapies, targeting serious diseases such as Parkinson’s disease for patients in Japan and globally.
Average Trading Volume: 9,612,137
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen941.8B
Learn more about 4506 stock on TipRanks’ Stock Analysis page.